Type 1 diabetes: where are we in 2017?

Area of Science:

• Immunology
• Endocrinology
• Metabolic Diseases

Background:

• Type 1 diabetes mellitus (T1DM) is a chronic autoimmune condition characterized by the immune system's destruction of pancreatic beta cells, leading to absolute insulin deficiency.
• This deficiency results in profound metabolic dysregulation and necessitates lifelong insulin replacement therapy.
• The long-term health consequences of T1DM include devastating microvascular and macrovascular complications, significantly impacting patient morbidity and mortality.

Purpose of the Study:

• To provide an overview of the current understanding of Type 1 diabetes mellitus.
• To highlight the advancements in medical therapies since the discovery of insulin.
• To emphasize the ongoing efforts and the need for further research towards a definitive cure for T1DM.

Main Methods:

• This abstract is based on a review of existing literature and established knowledge regarding Type 1 diabetes mellitus.
• It synthesizes information on the pathophysiology, current treatments, and future research directions.
• No new experimental data were generated for this overview.

Main Results:

• Medical therapies developed since the discovery of insulin have significantly improved long-term survival rates for individuals with Type 1 diabetes.
• Despite therapeutic advancements, the complete eradication of the disease and its complications has not yet been achieved.
• The autoimmune destruction of beta cells remains the central challenge in managing and potentially curing T1DM.

Conclusions:

• Type 1 diabetes mellitus is a complex autoimmune disease requiring continuous management and research.
• Significant progress has been made in improving patient outcomes, but a cure is still elusive.
• Continued dedicated research is essential to overcome the remaining hurdles and ultimately eliminate Type 1 diabetes mellitus.